lansoprazole has been researched along with Cystic Fibrosis in 5 studies
Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.
Cystic Fibrosis: An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.
Excerpt | Relevance | Reference |
---|---|---|
" In this prospective open study of 14 children with cystic fibrosis (CF), we evaluated the effect of 1 year adjuvant therapy with lansoprazole, a proton pump inhibitor (PPI), on growth, fecal fat loss, body composition and lung function." | 9.09 | Changes in pulmonary hyperinflation and bronchial hyperresponsiveness following treatment with lansoprazole in children with cystic fibrosis. ( Donckerwolcke, R; Forget, PP; Hendriks, JJ; Kester, AD; Wouters, EF, 2001) |
" In this prospective open study of 14 children with cystic fibrosis (CF), we evaluated the effect of 1 year adjuvant therapy with lansoprazole, a proton pump inhibitor (PPI), on growth, fecal fat loss, body composition and lung function." | 5.09 | Changes in pulmonary hyperinflation and bronchial hyperresponsiveness following treatment with lansoprazole in children with cystic fibrosis. ( Donckerwolcke, R; Forget, PP; Hendriks, JJ; Kester, AD; Wouters, EF, 2001) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (20.00) | 18.2507 |
2000's | 3 (60.00) | 29.6817 |
2010's | 1 (20.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chung, WJ | 1 |
Goeckeler-Fried, JL | 1 |
Havasi, V | 1 |
Chiang, A | 1 |
Rowe, SM | 1 |
Plyler, ZE | 1 |
Hong, JS | 1 |
Mazur, M | 1 |
Piazza, GA | 1 |
Keeton, AB | 1 |
White, EL | 1 |
Rasmussen, L | 1 |
Weissman, AM | 1 |
Denny, RA | 1 |
Brodsky, JL | 1 |
Sorscher, EJ | 1 |
Tran, TM | 1 |
Van den Neucker, A | 1 |
Hendriks, JJ | 2 |
Forget, P | 1 |
Forget, PP | 4 |
Kester, AD | 1 |
Donckerwolcke, R | 1 |
Wouters, EF | 1 |
Hendriks, HJ | 2 |
van Kreel, B | 1 |
ter Heide, H | 1 |
Heijmans, H | 1 |
Menheere, PP | 1 |
Spaapen, LJ | 1 |
Bakker, JA | 1 |
1 trial available for lansoprazole and Cystic Fibrosis
Article | Year |
---|---|
Changes in pulmonary hyperinflation and bronchial hyperresponsiveness following treatment with lansoprazole in children with cystic fibrosis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adipose Tissue; Adolescent; Body Composition; Body Height; | 2001 |
4 other studies available for lansoprazole and Cystic Fibrosis
Article | Year |
---|---|
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regu | 2016 |
Effects of a proton-pump inhibitor in cystic fibrosis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Anthropometry; Celiac Disease; Child; Ch | 1998 |
Effects of therapy with lansoprazole on intestinal permeability and inflammation in young cystic fibrosis patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Anti-Infective Agents; Biomarkers; Child; Child | 2001 |
Are children with cystic fibrosis who are treated with a proton-pump inhibitor at risk for vitamin B(12) deficiency?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Case-Control Studies; Child; Child, Preschool; | 2001 |